Cervicogenic headache: the specific features of complex therapy with Amelotex and CompligamV

• Published in: Nevrologii͡a︡, neĭropsikhiatrii͡a︡, psikhosomatika Vol. 2; no. 2; pp. 58 - 62
• Main Author: M. L. Pospelova
• Format: Journal Article
• Language: Russian
• Published: IMA-PRESS LLC 13.06.2010
• Subjects: amelotex; cervicogenic headache; combined therapy; compligamv; efficiency; endothelial dysfunction; open-label study; tolerability
• ISSN: 2074-2711; 2310-1342
• DOI: 10.14412/2074-2711-2010-86

An open-labeled study of the efficiency and tolerance of complex injection therapy with Amelotex in a dose of 15 mg/day for 6 days and CompligamV in a dose of one ampoule for 15 days was conduced in 30 patients (24 women and 6 men) aged 45 to 71 years with chronic cervicogenic headache (CGH) (its duration of 2 months to 10 years). The Numerical Rating Scale (NRS), the Visual Analog Scale (VAS), the McGill Pain Questionnaire (MPQ), and the Brief Pain Inventory (BPI) developed by C.S. Cleeland were used to rate different characteristics of pain and to evaluate the efficiency of treatment. Laboratory redetermination of the levels of von Willebrand factor, factor VIII, antithrombin III, D-dimer, and homocysteine was made in 10 patients to study hemostatic parameters. Combined injection therapy with Amelotex and CompligamV in patients with CGH reduced the intensity of acute and chronic pain, by affecting both the sensory-discriminative and affective-motivational pain components. The therapy did not worsen endothelial dysfunction, a marker of activated blood coagulation; there was a rise in the content of antithrombin III (within the normal range). Combined injection therapy with Amelotex and CompligamV was observed to be well tolerated and to cause no adverse reactions.